Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
0.8700
-0.0500 (-5.43%)
Oct 10, 2025, 12:16 PM EDT - Market open
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
91
Market Cap
85.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Dec 31, 2018 | - | - | - |
Dec 31, 2017 | - | - | - |
Dec 31, 2016 | - | - | - |
Dec 31, 2015 | - | - | - |
Dec 31, 2014 | - | - | - |
Dec 31, 2013 | - | - | - |
Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMUX News
- 9 days ago - Immunic to Participate in Scientific and Investor Conferences in October - PRNewsWire
- 15 days ago - Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis - PRNewsWire
- 4 weeks ago - Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis - PRNewsWire
- 5 weeks ago - Immunic to Participate in Investor and Scientific Conferences in September - PRNewsWire
- 2 months ago - Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis - PRNewsWire
- 4 months ago - Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted - Seeking Alpha
- 4 months ago - Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS - PRNewsWire